{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T06:04:22Z","timestamp":1779602662335,"version":"3.53.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"W. L. Gore & Associates, Inc. Medical Products Division, Flagstaff, Arizona, USA"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vascular"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the differences in aneurysmal sac regression after endovascular aortic repair (EVAR) of abdominal aortic aneurysms (AAAs) in patients with and without dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective analysis of 3453 patients from an international prospective registry (Europe, United States of America, Brazil, Australia, and New Zealand) of patients treated with the GORE\u00ae EXCLUDER\u00ae endograft. All scheduled EVARs for infrarenal AAAs between 2014 and 2016 with complete 6-year follow-up imaging data were included. Logistic regression analysis was performed to assess changes in aneurysm diameter based on dyslipidemia after adjusting for sex, age, body mass index, tobacco use, hypertension, coronary artery disease, aneurysm diameter, aneurysm neck length, and aneurysm neck angle. The secondary outcomes included all-cause mortality, stroke\/transient ischemic attack (TIA), paraplegia\/paraparesis\/spinal cord ischemia, reintervention, endoleaks, and aortic rupture. A control group of patients without dyslipidemia with similar age and comorbidities was selected using propensity scores and matched using a 1:1 scheme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 3453 patients, 85.3% in the non-dyslipidemia group and 85.5% in the dyslipidemia group were men. The mean age was 73.5 \u00b1 8.8\u00a0years for the non-dyslipidemia group and 73.4 \u00b1 8.2 years for the dyslipidemia group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .001). The mean body mass index was 26.7 \u00b1 4.9\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for the non-dyslipidemia group, whereas it was 28.0 \u00b1 5.2\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for the dyslipidemia group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .001). Overall, 2269 patients (64.0%) were identified as having dyslipidemia. After propensity score matching (PSM), the dyslipidemia group had higher rates of hypertension (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .001), TIA (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .006), carotid disease (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .002), coronary artery bypass grafting (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .005), congestive cardiac failure (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .018), and peripheral artery disease (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .001). The indications for device placement were similar between the groups. After PSM, the non-dyslipidemia group was more likely to be treated off-label (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .030) and to have an aneurysm neck length of &lt;15\u00a0mm (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .035). There was no significant difference in the sac size changes within 1 year (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .7) or 6\u00a0years (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .14) between the groups. After PSM, all-cause mortality was 6.7% in individuals with dyslipidemia and 10.6% in those without (p = .018). However, there were no significant differences in aortic-related mortality between the overall (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .571) and the matched (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .662) populations. The rates of reintervention, stroke\/transient ischemic attack, and spinal cord ischemia were not significantly different. Among patients with dyslipidemia, larger aneurysm size at 1 year (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .037) and increased age at 6\u00a0years (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .001) were associated with sac expansion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this comprehensive real-world study of patients who underwent EVAR with the GORE\u00ae EXCLUDER endoprosthesis found that dyslipidemia did not increase endoleak rates or worsen imaging outcomes over 6\u00a0years. Overall, these findings suggest that dyslipidemia does not negatively impact EVAR outcomes and may indicate improved long-term care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17085381251377316","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:37:39Z","timestamp":1758195459000},"page":"525-537","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term impact of dyslipidemia on sac dynamics after endovascular aortic repair for abdominal aortic aneurysms in the GREAT registry: An insight in dyslipidemia using propensity matched controls"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-0382","authenticated-orcid":false,"given":"Bibombe P","family":"Mwipatayi","sequence":"first","affiliation":[{"name":"Royal Perth Hospital"},{"name":"University of Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Dodd","sequence":"additional","affiliation":[{"name":"Royal Perth Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon D","family":"Thomas","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital and Community Health Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-6785","authenticated-orcid":false,"given":"Elizabeth L","family":"Chou","sequence":"additional","affiliation":[{"name":"Smidt Heart Institute, Cedars-Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Milner","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Azizzadeh","sequence":"additional","affiliation":[{"name":"Smidt Heart Institute, Cedars-Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santi","family":"Trimarchi","sequence":"additional","affiliation":[{"name":"University of Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan MM","family":"Heyligers","sequence":"additional","affiliation":[{"name":"Elisabeth TweeSteden Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dittmar","family":"B\u00f6ckler","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P","family":"Schlaich","sequence":"additional","affiliation":[{"name":"University of Western Australia"},{"name":"Royal Perth Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.01.076"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(03)00924-8"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9516"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820937432"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2018.04.050"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2020.08.110"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.014902"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2016.12.131"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2003.170"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2003.212"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2023.10.033"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/154.3.236"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a017997"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.10.017"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.802074"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2015.08.024"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2014.12.016"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.12.040"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.12.018"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.7343"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2002.123676"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.08.016"},{"key":"e_1_3_7_24_2","first-page":"169","article-title":"[New insights in the pathogenesis of prothrombotic state associated with hypercholesterolemia]","volume":"95","author":"Ferroni P","year":"2004","unstructured":"Ferroni P, Basili S, Dav\u00ec G. [New insights in the pathogenesis of prothrombotic state associated with hypercholesterolemia]. Recent Progress Med 2004; 95: 169\u2013178, (in Italian).","journal-title":"Recent Progress Med"},{"key":"e_1_3_7_25_2","first-page":"829","article-title":"Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin","volume":"14","author":"Wada H","year":"1992","unstructured":"Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829\u2013834.","journal-title":"Clin Ther"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000025419.95769.F0"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1208378"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2014.14308"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2022.03.010"},{"key":"e_1_3_7_30_2","first-page":"e14841","article-title":"The impact of endograft selection on outcomes following treatment outside of instructions for use (IFU) in endovascular abdominal aortic aneurysm repair (EVAR)","volume":"13","author":"Barry IP","year":"2021","unstructured":"Barry IP, Turley LP, Mwipatayi DL, et al. The impact of endograft selection on outcomes following treatment outside of instructions for use (IFU) in endovascular abdominal aortic aneurysm repair (EVAR). Cureus 2021; 13: e14841.","journal-title":"Cureus"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2020.08.007"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2022.07.008"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a001081"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029761"}],"container-title":["Vascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17085381251377316","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17085381251377316","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17085381251377316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T05:16:40Z","timestamp":1779599800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17085381251377316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/17085381251377316"],"URL":"https:\/\/doi.org\/10.1177\/17085381251377316","relation":{},"ISSN":["1708-5381","1708-539X"],"issn-type":[{"value":"1708-5381","type":"print"},{"value":"1708-539X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}